🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to health experts.

An International Health Concern

Cases of gonorrhoea are increasing worldwide, with estimates suggesting in excess of 82 million infections each year. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the reality of growing infection rates, the spread of superbugs and the very limited therapeutic options currently available.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the US FDA in recent days for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This authorization marks a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Data and Global Access

According to findings released by a prominent scientific publication, zoliflodacin cured more than 90% of cases of the STI. This establishes an comparable level with the existing first-line therapy, which uses two antibiotics. The study enrolled hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Doctors treating patients have shared hope. Having a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is deemed crucial to reduce the burden of the illness for patients and to prevent the spread of untreatable gonorrhoea worldwide.